Axsome Therapeutics Announces Positive Phase 3 Trial Results for AXS-12 in Treating Narcolepsy at SLEEP 2025 Conference

Reuters

2025/06/11

Axsome <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Positive Phase 3 Trial Results for AXS-12 in Treating Narcolepsy at SLEEP 2025 Conference

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company focused on central nervous system disorders, announced multiple presentations on their treatments AXS-12 and solriamfetol at the 39th annual meeting of the Associated Professional Sleep Societies (APSS), SLEEP 2025, held from June 8-11, 2025, in Seattle, Washington. The presentations included results from clinical trials and real-world studies. Notably, the results of the Phase 3 SYMPHONY trial and the ENCORE trial for AXS-12 in narcolepsy were presented, highlighting its impact on symptom severity and functional impairment. Additionally, solriamfetol was discussed in the context of excessive daytime sleepiness in patients with obstructive sleep apnea. The presentations were scheduled for June 11, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9466491-en) on June 11, 2025, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2542585001"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542585001\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2542585001?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-11 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542585001","market":"nz","top_or_hot":-1,"title":"Axsome Therapeutics Announces Positive Phase 3 Trial Results for AXS-12 in Treating Narcolepsy at SLEEP 2025 Conference","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Axsome <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Phase 3 Trial Results for AXS-12 in Treating Narcolepsy at SLEEP 2025 Conference\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/AXSM\">Axsome Therapeutics, Inc.</a> (NASDAQ: AXSM), a biopharmaceutical company focused on central nervous system disorders, announced multiple presentations on their treatments AXS-12 and solriamfetol at the 39th annual meeting of the Associated Professional Sleep Societies (APSS), SLEEP 2025, held from June 8-11, 2025, in Seattle, Washington. The presentations included results from clinical trials and real-world studies. Notably, the results of the Phase 3 <a href=\"https://laohu8.com/S/SIHL.UK\">SYMPHONY</a> trial and the ENCORE trial for AXS-12 in narcolepsy were presented, highlighting its impact on symptom severity and functional impairment. Additionally, solriamfetol was discussed in the context of excessive daytime sleepiness in patients with obstructive sleep apnea. The presentations were scheduled for June 11, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9466491-en) on June 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Axsome Therapeutics Announces Positive Phase 3 Trial Results for AXS-12 in Treating Narcolepsy at SLEEP 2025 Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAxsome Therapeutics Announces Positive Phase 3 Trial Results for AXS-12 in Treating Narcolepsy at SLEEP 2025 Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-11 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Axsome <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Positive Phase 3 Trial Results for AXS-12 in Treating Narcolepsy at SLEEP 2025 Conference\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/AXSM\">Axsome Therapeutics, Inc.</a> (NASDAQ: AXSM), a biopharmaceutical company focused on central nervous system disorders, announced multiple presentations on their treatments AXS-12 and solriamfetol at the 39th annual meeting of the Associated Professional Sleep Societies (APSS), SLEEP 2025, held from June 8-11, 2025, in Seattle, Washington. The presentations included results from clinical trials and real-world studies. Notably, the results of the Phase 3 <a href=\"https://laohu8.com/S/SIHL.UK\">SYMPHONY</a> trial and the ENCORE trial for AXS-12 in narcolepsy were presented, highlighting its impact on symptom severity and functional impairment. Additionally, solriamfetol was discussed in the context of excessive daytime sleepiness in patients with obstructive sleep apnea. The presentations were scheduled for June 11, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9466491-en) on June 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NDAQ","symbol_name":"纳斯达克OMX交易所","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nNDL2B2FWY:1","article_id":"2542585001","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542585001","pubTimestamp":1749639630,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Axsome Therapeutics, Inc. , a biopharmaceutical company focused on central nervous system disorders, announced multiple presentations on their treatments AXS-12 and solriamfetol at the 39th annual meeting of the Associated Professional Sleep Societies , SLEEP 2025, held from June 8-11, 2025, in Seattle, Washington. The presentations included results from clinical trials and real-world studies. Notably, the results of the Phase 3 SYMPHONY trial and the ENCORE trial for AXS-12 in narcolepsy were presented, highlighting its impact on symptom severity and functional impairment. Additionally, solriamfetol was discussed in the context of excessive daytime sleepiness in patients with obstructive sleep apnea. The presentations were scheduled for June 11, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shou","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"NDAQ":"纳斯达克OMX交易所","AXSM":"Axsome Therapeutics, Inc."},"translate_title":"Axsome Therapeutics在SLEEP 2025会议上宣布AXS-12治疗发作性睡病的积极3期试验结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AXSM":0.9,"NDAQ":0.9},"content_text":"Axsome Therapeutics Announces Positive Phase 3 Trial Results for AXS-12 in Treating Narcolepsy at SLEEP 2025 Conference\n    \n\nAxsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company focused on central nervous system disorders, announced multiple presentations on their treatments AXS-12 and solriamfetol at the 39th annual meeting of the Associated Professional Sleep Societies (APSS), SLEEP 2025, held from June 8-11, 2025, in Seattle, Washington. The presentations included results from clinical trials and real-world studies. Notably, the results of the Phase 3 SYMPHONY trial and the ENCORE trial for AXS-12 in narcolepsy were presented, highlighting its impact on symptom severity and functional impairment. Additionally, solriamfetol was discussed in the context of excessive daytime sleepiness in patients with obstructive sleep apnea. The presentations were scheduled for June 11, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axsome Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9466491-en) on June 11, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"conferences,dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}